National Jewish Health: Brensocatib Reduces Bronchiectasis Exacerbations
September 19, 2020
September 19, 2020
DENVER, Sept. 19 (TNSRes) -- National Jewish Health, a respiratory hospital, issued the following news release:
Researchers at National Jewish Health and around the world have reported that the experimental medication brensocatib reduces exacerbations of bronchiectasis by approximately 40 percent as learned in a phase 2 trial.
Bronchiectasis is chronic inflammation and dilation of the airways that results from damage caused by respiratory infections, genetic diseases su . . .
Researchers at National Jewish Health and around the world have reported that the experimental medication brensocatib reduces exacerbations of bronchiectasis by approximately 40 percent as learned in a phase 2 trial.
Bronchiectasis is chronic inflammation and dilation of the airways that results from damage caused by respiratory infections, genetic diseases su . . .